Communicating the benefits and harms of treatments

被引:27
作者
Akobeng, A. K. [1 ]
机构
[1] Booth Hall Childrens Hosp, Cent Manchester & Manchester Childrens Univ Hosp, Dept Paediat Gastroenterol, Manchester M9 7AA, Lancs, England
关键词
D O I
10.1136/adc.2008.137083
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Although various measures can be used to describe the benefits and harms of treatments, not all of these clearly show the benefits or otherwise of treatments in a clinically useful way. Relative risk and relative risk reduction are commonly used to describe the results of studies, but they are of limited clinical usefulness as they do not take baseline risks into account and tend to exaggerate the results of studies. Absolute risk measures such as the number needed to treat (NNT) and the number needed to harm (NNH) allow risk to be expressed in a much more clinically relevant way. The absolute risk measures reflect baseline risk and more accurately indicate the magnitude of the treatment effect. However, because they vary according to the baseline risk of the population, they are of limited generalisability, and the published NNT of a treatment in one population cannot be directly applied to another population with a different baseline risk. There are, however, a number of simple methods which can allow us to estimate NNTs or NNHs for our own patients based on published data. The benefits of a treatment (expressed as the NNT) and the harms of the treatment (expressed as the NNH) can be combined into a single ratio called the likelihood of being helped or harmed (LHH). LHH can be adjusted for individual patients by taking account of their own values and unique circumstances.
引用
收藏
页码:710 / 713
页数:4
相关论文
共 11 条
[1]   Understanding measures of treatment effect in clinical trials [J].
Akobeng, AK .
ARCHIVES OF DISEASE IN CHILDHOOD, 2005, 90 (01) :54-56
[2]  
[Anonymous], 2005, Evidence-Based Medicine: How to practice and teach EBM. 3
[3]  
Chatellier G, 1996, BRIT MED J, V312, P426
[4]   How to make clinical decisions from statistics [J].
Cockburn, David M. .
CLINICAL AND EXPERIMENTAL OPTOMETRY, 2006, 89 (03) :176-183
[5]  
DiCenso A, 2001, Evid Based Nurs, V4, P36, DOI 10.1136/ebn.4.2.36
[6]   How to estimate treatment effects from reports of clinical trials. II: Dichotomous outcomes [J].
Herbert, RD .
AUSTRALIAN JOURNAL OF PHYSIOTHERAPY, 2000, 46 (04) :309-313
[7]   A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1-to 24-month-old pediatric patients after surgery under general anesthesia [J].
Khalil, SN ;
Roth, AG ;
Cohen, IT ;
Simhi, E ;
Ansermino, JM ;
Bolos, ME ;
Coté, CJ ;
Hannallah, RS ;
Davis, PJ ;
Brooks, PB ;
Russo, MW ;
Anschuetz, GC ;
Blackburn, LM .
ANESTHESIA AND ANALGESIA, 2005, 101 (02) :356-361
[8]  
Last JM, 2001, DICT EPIDEMIOLOGY
[9]   Users' guides to the medical literature - XX. Integrating research evidence with the care of the individual patient [J].
McAlister, FA ;
Straus, SE ;
Guyatt, GH ;
Haynes, RB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (21) :2829-2836
[10]  
Schechtman E, 2002, VALUE HEALTH, V5, P431